Revolve Wealth Partners LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Revolve Wealth Partners LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 36.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 498 shares of the pharmaceutical company’s stock after selling 289 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Vertex Pharmaceuticals were worth $201,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Mutual Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 21 shares during the period. Daymark Wealth Partners LLC raised its position in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 22 shares in the last quarter. Grove Bank & Trust boosted its stake in Vertex Pharmaceuticals by 5.7% during the third quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock valued at $191,000 after buying an additional 22 shares during the period. Outlook Wealth Advisors LLC grew its position in Vertex Pharmaceuticals by 2.8% during the third quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock worth $415,000 after buying an additional 24 shares in the last quarter. Finally, Dunhill Financial LLC increased its stake in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

VRTX has been the subject of several recent analyst reports. Scotiabank boosted their price objective on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the stock a “sector perform” rating in a report on Monday, December 23rd. UBS Group increased their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Wells Fargo & Company reduced their target price on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $494.76.

Vertex Pharmaceuticals Stock Down 0.7 %

Shares of Vertex Pharmaceuticals stock opened at $440.68 on Wednesday. The company’s fifty day simple moving average is $434.90 and its two-hundred day simple moving average is $463.98. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.67 earnings per share. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.